RxDoctor Payments Data

Nathan Degn, OD

Optometrist · Salt Lake City, UTNPI 1619498375

Payments from drug & device makers

$382in general payments, 2019–2025

Across 15 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$125
  • Amgen$98
  • AbbVie$82
  • Biotissue Holdings Inc.$27
  • Sun Pharmaceutical Industries Inc.$19
  • Tarsus Pharmaceuticals, Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382 in reported general payments places this provider in the 30th percentile of 423 optometrist providers in Utah.

See all optometrist providers in Utah

Medicare billing

Part B allowed, 2024
$125,422
Medicare patients
717
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$45,910
LumiganBimatoprost33$17,210
Cyclosporine20$4,640
Alphagan PBrimonidine Tartrate12$4,284
Travoprost23$3,547
Latanoprost335$3,351
Prednisolone Acetate63$3,186
TafluprostTafluprost/Pf13$2,391
Tobramycin-DexamethasoneTobramycin/Dexamethasone34$1,782
Brimonidine Tartrate24$1,755
Fluorometholone18$1,395
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$789
Timolol Maleate101$771
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$281
Dorzolamide Hcl27$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$82$67,40488 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 423 optometrist providers in Utah.

Other optometrist in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →